PHARMADAN A/S: Financial statements 2024
CVR: 26524938
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
PHARMADAN A/S (CVR 26524938) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -5,840,517 and a net result of DKK -5,113,611 compared with DKK -4,167,683 the year before. Equity in the 2024 report amounted to DKK -13,528,484.
- Gross Profit
- DKK -5,840,517
- Profit/Loss
- DKK -5,113,611
- Equity
- DKK -13,528,484
- Total Assets
- DKK 6,821,830
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -5.8M | -5.1M | -13.5M | - |
| 2023 | - | -4.9M | -4.2M | -8.4M | - |
| 2022 | - | -3.1M | -2.8M | -4.2M | - |
| 2021 | - | -2.8M | -2.5M | -1.5M | - |
| 2020 | - | -8K | -1.6M | 1M | 3 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout PHARMADAN A/S
PHARMADAN A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 2002. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Peter Rørvig. The board consists of Helle Rørvig, Niels Ulrik Heine and Peter Rørvig. The company is owned by H&P Rørvig Holding A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -6,382,654 and a net result of DKK -5,426,641 compared with DKK -5,113,611 the year before. Equity in the 2025 report amounted to DKK -18,955,125.